Highest-materiality recent filing
Vor Biopharma raises $75M via private placement with TCGX for telitacicept development
Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.
Vor Biopharma reports preliminary cash of ~$450M as of Dec 31, 2025
Cash, cash equivalents and short-term investments ~$450M as of Dec 31, 2025 (preliminary, unaudited).
Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting
Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.
Vor Bio raises $150M in private placement; appoints two new directors
Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.
Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced
Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.
10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).
Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms
Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.
Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China
Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.
Vor Biopharma announces 1-for-20 reverse stock split effective Sept 18, 2025
Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on September 18, 2025.
Vor Biopharma files corporate presentation; no material new disclosures
Filing furnishes a September 2025 corporate presentation under Item 7.01.
Stockholders approved reverse stock split in range 1-for-5 to 1-for-30; board to determine ratio.
Vor Biopharma announces three director resignations, appoints Sarah Reed
Joshua Resnick, Matthew Patterson, and David Lubner resigned from the Board effective Aug 25-26, 2025; no disagreement cited.
Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors
Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.
Vor Biopharma appoints Sandesh Mahatme as CFO and Chief Business Officer
Sandesh Mahatme appointed CFO, Principal Financial Officer and Principal Accounting Officer, effective July 9, 2025.
Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO
License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.
Vor Biopharma shareholders OK share increase to 800M, re-elect directors
Authorized common shares increased from 400M to 800M; approved by 65.5M votes for vs 7.7M against.
Vor Biopharma CEO Robert Ang designated Principal Financial Officer and Principal Accounting Officer
Board designated CEO Robert Ang as principal financial and accounting officer effective May 19, 2025.
On May 19, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s principal financial officer and principal accounting officer.
Max materiality 0.90 · Median 0.60 · Most common event other_material